Search results for "From ACP Journal Club"
In type 2 diabetes, early metformin plus vildagliptin reduced treatment failure vs a stepwise approach
Despite this study's findings, clinicians should continue to follow guidelines and use metformin as the first-line drug intervention, then select from other drug classes when there is a compelling indication, advised an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/03/13/7.htm
13 Mar 2020
In newly diagnosed type 2 diabetes mellitus, a Mediterranean diet (vs. a low-fat diet) delayed start of glucose-lowering drugs
Patients who were randomized to a low-carbohydrate Mediterranean diet shortly after type 2 diabetes diagnosis delayed their need for medication compared to those put on a low-fat diet in an Italian trial.
https://diabetes.acponline.org/archives/2014/10/10/5.htm
10 Oct 2014
Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD
Baseline kidney disease, albuminuria, and cardiovascular disease (CVD) status may help determine which patients will benefit most from sodium-glucose cotransporter-2 inhibitors, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/11/08/7.htm
8 Nov 2019
Continuous glucose monitoring reduced hypoglycemia over 6 months
The positive results of a trial of continuous glucose monitoring in type 1 diabetes patients ages 60 years and older support recommending the technology to this group, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/12/11/10.htm
11 Dec 2020
Review: In patients with type 2 diabetes who fast, sitagliptin reduces hypoglycemia more than sulfonylurea
Patients who took sitagliptin were significantly less likely to have hypoglycemia during Ramadan, according to a systematic review.
https://diabetes.acponline.org/archives/2015/11/13/6.htm
13 Nov 2015
In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years
These long-term follow-up data show no legacy effect from intensive glucose control on cardiovascular (CV) events, differing from the results of the United Kingdom Prospective Diabetes Study, an ACP Journal Club commentary noted.
https://diabetes.acponline.org/archives/2019/10/11/8.htm
11 Oct 2019
In high-risk pregnant women, an individualized lifestyle intervention reduced gestational diabetes mellitus
The intervention in the Finnish study targeted women with previous gestational diabetes mellitus or a body mass index of 30 kg/m2 or greater.
https://diabetes.acponline.org/archives/2016/01/08/5.htm
8 Jan 2016
In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide
This industry-funded trial of tirzepatide, a unimolecular dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, heralds a new era of “twincretins” in diabetes management, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/11/12/6.htm
12 Nov 2021
Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality
The meta-analysis included 37 trials that compared canagliflozin, dapagliflozin, or empagliflozin to placebo or other active antidiabetic treatments.
https://diabetes.acponline.org/archives/2017/02/10/6.htm
10 Feb 2017
Some antimicrobials increased admissions and ED visits for hypoglycemia in older users of glipizide or glyburide
A study of Texas Medicare patients who took either glipizide or glyburide found that those who were also prescribed certain antibiotics had a much higher rate of hypoglycemic events than those taking an antibiotic not expected to interact with sulfonylureas.
https://diabetes.acponline.org/archives/2015/03/13/7.htm
13 Mar 2015